Antibiotics and resistance of uropathogens

EAU Update Series

Volumn 2, Issue 3, 2004, Pages 125-135

  Wagenlehner, F M E ^a   Naber, K G ^a  

^a Urologische Klinik   (Germany)

Author keywords

Antibiotic resistance; Resistance mechanisms; Urinary tract infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MEZLOCILLIN; NITROFURANTOIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GENETICS; BACTERIAL MUTATION; CHRONIC DISEASE; CITROBACTER; CLINICAL PRACTICE; COMMUNICABLE DISEASE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG INACTIVATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TRANSPORT; DRUG USE; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; EUROPE; GERMANY; HOSPITAL INFECTION; HUMAN; IMMUNOPATHOLOGY; INFECTION COMPLICATION; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PATHOGENESIS; PROTEIN SYNTHESIS; PROTEUS; PSEUDOMONAS; STAPHYLOCOCCUS; URINARY TRACT INFECTION; UROLOGY;

EID: 4544243659     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euus.2004.06.003     Document Type: Article

References (42)

1. Gastmeier P. Kampf G. Wischnewski N. Hauer T. Schulgen G. Schumacher M. Daschner F. Ruden H. Prevalence of nosocomial infections in representative German hospitals J. Hosp. Infect 38 1998 37-49
2. Gupta K. Hooton T.M. Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections Ann. Intern. Med. 135 2001 41-50
3. Talan D.A. Stamm W.E. Hooton T.M. et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial JAMA 283 2000 1583-1590
4. Jones R.N. Kugler K.C. Pfaller M.A. Winokur P.L. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997 Diagn. Microbiol. Infect Dis. 35 1999 55-63
5. Gordon K.A. Jones R.N. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000) Diagn. Microbiol. Infect Dis. 45 2003 295-301
6. Mathai D. Jones R.N. Pfaller M.A. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America) Diagn. Microbiol. Infect Dis. 40 2001 129-136
7. Bouza E. San Juan R. Muñoz P. Voss A. Kluytmans J on behalf of the Co-operative Group of the European Study Group on Nosocomial Infections (ESGNI). A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study) Clin Microbiol. Infect 7 2001 523-531
8. Bjerklund-Johansen T. ESIU-board members. Pan-European-prevalence study on nosocomially acquired UTI (NAUTI). http://www.pep.trentt.com/statistics.php (14.03.2004).
9. Wagenlehner F.M.E. Niemetz A. Naber K.G. Erregerspektrum und Antibiotikaresistenz von Erregern bei stationären urologischen Patienten mit Harnwegsinfektionen (1994-2001) und Konsequenzen für die Antibiotikatherapie Urologe [A] 43 2003 13-25
10. Karlowsky J.A. Kelly L.J. Thornsberry C. et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking resistance in the United States today. The Surveillance Network Int. J. Antimicrob. Agents 19 2002 21-31
11. Karlowsky J.A. Kelly L.J. Thornsberry C. Jones M.E. Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States Antimicrob. Agents Chemother 46 2002 2540-2545
12. Morrissey I, Farrell DJ, Robbins M, Werling H-O, Felingham D. Surveillance of the antibiotic susceptibility of urinary tract infection (UTI) pathogens in Europe from outpatients (OUT) and inpatients (IN) during 1999/2000. Clin. Microbiol. Infect. 2003;9(Suppl 1) [Abstract].
13. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project J. Antimicrob. Chemother 51 2003 69-76
14. Jones R.N. Beach M.L. Pfaller M.A. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn. Microbiol. Infect Dis. 41 2001 161-163
15. Luna C.M. Vujacich P. Niedermann M.S. Vay C. Gherardi C. Matera J. Jolly E.C. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia Chest 111 1997 676-685
16. Montravers P. Gauzit R. Muller C. Marmuse J.P. Fichelle A. Desmonts J.M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy Clin Infect Dis 23 1996 486-494
17. Drlica K. Zhao X. DNA gyrase, topoisomerase, and the 4-quinolones Microbiol. Molecular Biol. Rev. 61 1997 377-392
18. Lehn N. Mechanismen der Resistenzentwicklung gegen Antibiotika, Epidemiologie. In: Adam D, Doerr HW, Link H, Lode H, editors. Die Infektiologie. Berlin: Springer; 2004. p. 82-98.
19. Pechere J.C. Michea-Hamzhepour M. Kohler T. Antibiotic efflux, a mechanism of multiple resistance in Pseudomonas aeruginosa Bull Acad. Natl. Med. 182 1998 599-612
20. Piddock L.J. Mechanisms of fluoroquinolone resistance: an update 1994-1998 Drugs 58 Suppl 2 1999 11-18
21. Tanaka M. Onodera Y. Uchida Y. Sato K. Hayakawa I. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus Antimicrob Agents Chemother 41 1997 2362-2366
22. Linde H.J. Schmidt M. Fuchs E. Reischl U. Niller H.H. Lehn N. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci Antimicrob Agents Chemother 45 2001 1553-1557
23. Navia M.M. Ruiz J. Ribera A. de Anta M.T. Vila J. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii J. Antimicrob. Chemother 44 1999 743-748
24. Fontana R. Ligozzi M. Pittaluga F. Satta G. Intrinsic penicillin resistance in enterococci Microb. Drug Resist 2 1996 209-213
25. Marshall C.G. Broadhead G. Leskiw B.K. Wright G.D. D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB Proc. Natl. Acad. Sci. U.S.A. 94 1997 6480-6483
26. Burchall J.J. Elwell L.P. Fling M.E. Molecular mechanisms of resistance to trimethoprim Rev. Infect Dis. 4 1982 246-254
27. Then R.L. Mechnaisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole Rev. Infect Dis. 4 1982 261-269
28. Park H. Bradrick T.D. Howell E.E. A glutamine 67 → histidine mutation in homotetrameric R67 dihydrofolate reductase results in four mutations per single active site pore and causes substantial substrate and cofactor inhibition Protein Eng. 10 1997 1415-1424
29. Livermore D.M. Antibiotic resistance in staphylococci Int. J. Antimicrob. Agents 16 Suppl 1 2000 3-10
30. Stapleton P. Wu P.J. King A. Shannon K. French G. Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Eschericia coli Antimicrob. Agents Chemother 39 1995 2478-2483
31. Chaves J. Ladona M.G. Segura C. Coira A. Reig R. Ampurdanse C. SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae Antimicrob. Agents Chemother 45 2001 2856-2861
32. Yang Y.J. Livermore D.M. Williams R.J. Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae J. Med. Microbiol. 25 1988 227-233
33. Bonnet R. De champs C. Sirot D. Chanal C. Labia R. Sirot J. Diversity of TEM mutants in Proteus mirabilis Antimicrob. Agents Chemother 43 1999 2671-2677
34. Patterson J.E. Extended-spectrum beta-lactamases Semin. Respir Infect 15 2000 299-307
35. Jones R.N. Resistance patterns among nosocomial pathogens: trends over the past few years Chest 119 2 Suppl 2001 397-404
36. Culebras E. Martinez J.L. Aminoglycoside resistance mediated by the bifunctional enzyme 6′-N-aminoglycoside acetyltransferase-2″-O-aminoglycoside phosphotransferase Front Biosci. 4 1999 1-8
37. Aminoglycoside resistance study groups: The most frequently occurring amoinoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J Chemother 1995;7(Suppl 2):17-30.
38. Lepper P.M. Grusa E. Reichl H. Högel J. Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa Antimicrob. Agents Chemother 46 2002 2920-2925
39. Zhao X. Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies Clin Infect Dis 33 Suppl 3 2001 147-156
40. Baquero F. Negri M.-C. Morosini M.I. Blazquez J. Antibiotic-selective environments Clin Infect Dis 27 Suppl 1 1998 5-11
41. Bager F. Aarestrup F.M. Madsen M. Wegener H.C. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin Microb. Drug Resist 5 1999 53-56
42. Vogel F. Bodmann K.F. experts of the Paul-Ehrlich-Gesellschaft for Chemotherapy Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen Chemother J 13 2004 46-105